The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes

被引：36
作者：
Yin, Win L. [1 ]
Bain, Steve C. [1 ,2 ]
Min, Thinzar [2 ,3 ]
机构：
[1] Swansea Bay Univ Hlth Board, Singleton Hosp, Dept Diabet & Endocrinol, Swansea SA2 8QA, W Glam, Wales
[2] Swansea Univ, Med Sch, Diabet Res Grp, Swansea SA2 8PP, W Glam, Wales
[3] Swansea Bay Univ Hlth Board, Neath Port Talbot Hosp, Dept Diabet & Endocrinol, Swansea SA12 7BX, W Glam, Wales
来源：
DIABETES THERAPY | 2020年 / 11卷 / 04期
关键词：
Chronic kidney disease; Diabetes-related nephropathy; Diabetic nephropathy; Dipeptidyl peptidase-4 (DPP-4) inhibitors; Glucagon-like peptide-1 receptor agonists; Type; 2; diabetes; CARDIOVASCULAR OUTCOMES; KIDNEY-FUNCTION; LIRAGLUTIDE; GLP-1; EXENATIDE;
D O I：
10.1007/s13300-020-00798-x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This review examines the available literature on the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in type 2 diabetes mellitus. Diabetes is an important cause of end-stage renal disease requiring renal replacement therapy, and diabetic kidney disease is an independent risk factor for cardiovascular disease (CVD). GLP-1RAs are proven to be safe in terms of CVD, and some of them have been shown to have a beneficial effect on cardiovascular outcomes. The effect of GLP-1RAs on hard renal endpoints has yet to be established; to date, there have been no published GLP-1RA clinical trials with primary renal endpoints. In this review, we discuss the evidence for a renal protective role of GLP-1RAs, highlighting the secondary renal outcomes from recent cardiovascular outcome trials of this class of glucose-lowering therapies.
引用
收藏
页码：835 / 844
页数：10
相关论文
共 35 条
[1]   Diabetic Kidney Disease Challenges, Progress, and Possibilities [J].
Alicic, Radica Z. ;
Rooney, Michele T. ;
Tuttle, Katherine R. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (12) :2032-2045
[2]  
[Anonymous], 2019, RES STUDY SEE SEMAGL
[3]   Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial [J].
Bethel, M. Angelyn ;
Mentz, Robert J. ;
Merrill, Peter ;
Buse, John B. ;
Chan, Juliana C. ;
Goodman, Shaun G. ;
Iqbal, Nayyar ;
Jakuboniene, Neli ;
Katona, Brian ;
Lokhnygina, Yuliya ;
Lopes, Renato D. ;
Maggioni, Aldo P. ;
Ohman, Peter ;
Tankova, Tsvetalina ;
Bakris, George L. ;
Hernandez, Adrian F. ;
Holman, Rury R. .
DIABETES CARE, 2020, 43 (02) :446-452
[4]   Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction [J].
Chen, Yen-Ta ;
Tsai, Tzu-Hsien ;
Yang, Chih-Chau ;
Sun, Cheuk-Kwan ;
Chang, Li-Teh ;
Chen, Hung-Hwa ;
Chang, Chia-Lo ;
Sung, Pei-Hsun ;
Zhen, Yen-Yi ;
Leu, Steve ;
Chang, Hsueh-Wen ;
Chen, Yung-Lung ;
Yip, Hon-Kan .
JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11
[5]   Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment ( LIRA-RENAL): A Randomized Clinical Trial [J].
Davies, Melanie J. ;
Bain, Stephen C. ;
Atkin, Stephen L. ;
Rossing, Peter ;
Scott, David ;
Shamkhalova, Minara S. ;
Bosch-Traberg, Heidrun ;
Syren, Annika ;
Umpierrez, Guillermo E. .
DIABETES CARE, 2016, 39 (02) :222-230
[6]   The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes [J].
Drucker, Daniel J. ;
Nauck, Michael A. .
LANCET, 2006, 368 (9548) :1696-1705
[7]   Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists [J].
Dubois-Laforgue, D. ;
Boutboul, D. ;
Levy, D. J. ;
Joly, D. ;
Timsit, J. .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 103 (03) :E53-E55
[8]   The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential [J].
Fujita, Hiroki ;
Morii, Tsukasa ;
Fujishima, Hiromi ;
Sato, Takehiro ;
Shimizu, Tatsunori ;
Hosoba, Mihoko ;
Tsukiyama, Katsushi ;
Narita, Takuma ;
Takahashi, Takamune ;
Drucker, Daniel J. ;
Seino, Yutaka ;
Yamada, Yuichiro .
KIDNEY INTERNATIONAL, 2014, 85 (03) :579-589
[9]   Acute Interstitial Nephritis After Treatment With Liraglutide [J].
Gariani, Karim ;
de Seigneux, Sophie ;
Moll, Solange .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 63 (02) :347-347
[10]   Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria [J].
Gæde, P ;
Tarnow, L ;
Vedel, P ;
Parving, HH ;
Pedersen, O .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (11) :2784-2788
1234